Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Diagnostics

4.6 (573) · $ 26.50 · In stock

Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.

Pharmaceutical Company Developing Radiopharmaceuticals

First Participant Treated Using NorthStar Medical Radioisotopes' Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals' Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

News - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals - touchONCOLOGY

Copper radiopharmaceuticals for theranostic applications - ScienceDirect

News - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging

Clarity Pharmaceuticals on LinkedIn: First participants imaged in SAR-Bombesin prostate cancer trial in…

Clarity Receives US FDA response on its Theranostic Investigational New Drug (IND) Application that the study may proceed - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging